InvestorsHub Logo
Followers 62
Posts 7498
Boards Moderated 1
Alias Born 01/02/2003

Re: DAR53 post# 422932

Wednesday, 04/03/2024 6:28:13 PM

Wednesday, April 03, 2024 6:28:13 PM

Post# of 423945
Dar...I think you are correct" The following statement should be in a decision by the court...either by a judge or by a jury in the context of a trial...

"the simple step that all generic Vascepa companies should take to avoid infringing... is to simply indicate on their label that..."icosapentethyl is biosimilar to Vascepa, but only for use in very high triglycideremia"...That easy solution would solve Amarin's infringement dispute as to Vascepa.

Hikma might agree to this to avoid triple damages and other infringers might also agree, in order to avoid damages emanating from their own cases.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News